Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
Employer coverage of GLP-1 drugs for obesity has flatlined at 36%, and many companies are quietly finding workarounds instead of expanding benefits.
If you were hoping your employer would start picking up the tab for Ozempic or Wegovy, don't hold your breath. New survey data shows that 36% of employers cover GLP-1 drugs for both diabetes and weight loss — identical to 2025 figures and only a hair above the 34% recorded in 2024. That's not momentum. That's a stall.
The numbers tell a clear story: corporate America isn't rushing to absorb the cost of pricey GLP-1 medications for weight management. These drugs can run hundreds to thousands of dollars a month without coverage, meaning most workers are still largely on their own when it comes to affording them for obesity treatment.
Read more Citadel Drops US Suit Against Portofino, Targets Founder in UK →
What's more telling is the workaround culture quietly taking hold. Rather than expanding formal coverage, many employers are finding alternative routes — think narrower formularies, prior authorization hurdles, or steering employees toward lower-cost options. It keeps the headline coverage number technically stable while limiting real-world access for the people who need it.
For retail investors, this dynamic has direct implications. The explosive demand narrative for GLP-1 makers like Novo Nordisk and Eli Lilly hinges partly on broad insurance and employer adoption. If employers are capping exposure rather than opening the floodgates, the addressable market for weight-loss indications could grow slower than Wall Street bulls expect. Watch employer benefit trend reports — they're a leading indicator the Street often ignores.
Continue reading at US Top News and Analysis
